<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="brief-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title>Frontiers in Physiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Physiol.</abbrev-journal-title>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1514769</article-id>
<article-id pub-id-type="doi">10.3389/fphys.2025.1514769</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Connexin hemichannels and early atrophic signaling in muscle during sepsis</article-title>
<alt-title alt-title-type="left-running-head">Balboa et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphys.2025.1514769">10.3389/fphys.2025.1514769</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Balboa</surname>
<given-names>Elisa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2698554/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Saavedra</surname>
<given-names>Fujiko</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/392725/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cea</surname>
<given-names>Luis A.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/125115/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vargas</surname>
<given-names>An&#xed;bal A.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Regueira</surname>
<given-names>Tom&#xe1;s</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1431085/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>S&#xe1;ez</surname>
<given-names>Juan C.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1766587/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Center for Biomedical Research</institution>, <institution>School of Medicine</institution>, <institution>Faculty of Medicine</institution>, <institution>Universidad Finis Terrae</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Program of Reproductive Biology</institution>, <institution>Research and Innovation Center</institution>, <institution>School of Medicine</institution>, <institution>Faculty of Medicine</institution>, <institution>Universidad de los Andes</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Instituto de Ciencias Biom&#xe9;dicas</institution>, <institution>Facultad de Ciencias de la Salud</institution>, <institution>Universidad Aut&#xf3;noma de Chile</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Center for Integrative Biology</institution>, <institution>Faculty of Sciences</institution>, <institution>Universidad Mayor</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Intensive Care Department</institution>, <institution>Cl&#xed;nica Santa Mar&#xed;a</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Instituto de Neurociencias</institution>, <institution>Centro Interdisciplinario de Neurociencias de Valpara&#xed;so</institution>, <institution>Universidad de Valpara&#xed;so</institution>, <addr-line>Valpara&#xed;so</addr-line>, <country>Chile</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/999130/overview">Miao Zhang</ext-link>, Chapman University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2410453/overview">Zhifei Wang</ext-link>, St. John&#x2019;s University, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1646420/overview">J&#xfa;lia Costa de Sousa</ext-link>, Federal University of Rio de Janeiro, Brazil</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Elisa Balboa, <email>ebalboa@uft.cl</email>; Juan C. S&#xe1;ez, <email>juancarlos.saez@uv.cl</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>02</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1514769</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>10</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>01</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Balboa, Saavedra, Cea, Vargas, Regueira and S&#xe1;ez.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Balboa, Saavedra, Cea, Vargas, Regueira and S&#xe1;ez</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Sepsis pathogenesis is complex, and effective treatments are limited, leading to high mortality rates between 20% and 55%. Early identification of factors contributing to sepsis-related muscle dysfunction is critical for risk stratification and potential therapeutic development. The immune response during sepsis affects skeletal muscles, contributing to organ dysfunction and worsening prognosis. In this study, we explore the role of connexin hemichannels (Cx HCs) in the early changes in muscle homeostasis during sepsis. Using a cecal ligature and puncture (CLP)-induced sepsis model, we assessed IL-6 levels, weight loss, myofiber cross-sectional area, resting membrane potential, and connexin expression in control and Cx43/Cx45-deficient mice. CLP induced IL-6 elevation, sarcolemma permeabilization, reduced membrane potential, and activation of the ubiquitin&#x2013;proteasome pathway in control mice, while Cx43/45-deficient mice exhibited reduced all CLP-induced muscle alterations. These findings suggest that Cx43 and Cx45 are involved in the early development of muscle alterations during sepsis.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<fig>
<caption>
<p>Schematic Representation of Early Events in the CLP-Induced Sepsis Model and the Role of Connexins in Muscle Atrophy.</p>
</caption>
<graphic xlink:href="FPHYS_fphys-2025-1514769_wc_abs.tif"/>
</fig>
</p>
</abstract>
<kwd-group>
<kwd>resting membrane potential</kwd>
<kwd>muscles</kwd>
<kwd>inflammation</kwd>
<kwd>channeloapthy</kwd>
<kwd>connexin</kwd>
</kwd-group>
<contract-num rid="cn001">1141092 1231523 3160594 11230689</contract-num>
<contract-sponsor id="cn001">Agencia Nacional de Investigaci&#xf3;n y Desarrollo<named-content content-type="fundref-id">10.13039/501100020884</named-content>
</contract-sponsor>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Membrane Physiology and Membrane Biophysics</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Severe sepsis is the leading cause of death in Intensive Care Units (ICUs) world-wide, with mortality rates ranging from 20% to 55% (<xref ref-type="bibr" rid="B3">Bauer et al., 2020</xref>; <xref ref-type="bibr" rid="B29">Prest et al., 2022</xref>). In Chile, severe sepsis is highly prevalent in ICUs, with a case-fatality rate of 26.7%, highlighting its significant impact both nationally and globally (<xref ref-type="bibr" rid="B15">Dougnac et al., 2007</xref>).</p>
<p>Muscle atrophy is a significant consequence of sepsis, is highly prevalent and associated with high mortality (<xref ref-type="bibr" rid="B18">Fleischmann-Struzek et al., 2020</xref>; <xref ref-type="bibr" rid="B34">Singer et al., 2016</xref>). The main cause of death during sepsis is multiorgan failure (MOF), with muscle dysfunction being one of the key components (<xref ref-type="bibr" rid="B4">Bilevicius et al., 2001</xref>; <xref ref-type="bibr" rid="B22">Khan et al., 2008</xref>). Both respiratory and peripheral skeletal muscles are adversely affected by the systemic inflammatory response during acute and late sepsis (<xref ref-type="bibr" rid="B14">De et al., 2002</xref>; <xref ref-type="bibr" rid="B6">Callahan and Supinski, 2009</xref>). This muscle dysfunction is closely linked to a prolonged stay in the ICU and the need for mechanical ventilation, leading to higher mortality rates and long-term mobility issues (<xref ref-type="bibr" rid="B21">Hermans and Van den Berghe, 2015</xref>). Sepsis-associated muscle atrophy is characterized by a reduction in force-generating capacity and muscle wasting due to increased proteolysis over protein synthesis (<xref ref-type="bibr" rid="B16">Eikermann et al., 2006</xref>; <xref ref-type="bibr" rid="B35">Tiao et al., 1994</xref>; <xref ref-type="bibr" rid="B25">Lang et al., 2007</xref>). Several pathogenic mechanisms have been proposed to explain these changes, including mitochondrial dysfunction (MD) (<xref ref-type="bibr" rid="B5">Brealey et al., 2004</xref>), microvascular alterations, metabolic derangements, and oxidative stress (<xref ref-type="bibr" rid="B28">Prauchner, 2017</xref>; <xref ref-type="bibr" rid="B37">Wasyluk and Zwolak, 2021</xref>). Additionally, the sarcolemma becomes electrically unexcitable (<xref ref-type="bibr" rid="B36">Trojaborg et al., 2001</xref>; <xref ref-type="bibr" rid="B17">Fern&#xe1;ndez-Lorente et al., 2010</xref>) in the presence of elevated sarcoplasmic Ca<sup>2&#x2b;</sup> concentrations (<xref ref-type="bibr" rid="B2">Baracos et al., 1986</xref>), suggesting that acquired channelopathy may play a role in the muscle dysfunction observed during sepsis.</p>
<p>In our previous studies on late sepsis induced in mice, we showed evident skeletal muscle atrophy induced by cecal ligation and puncture (CLP), which was associated with the <italic>de novo</italic> expression connexin 39, 43, and 45 hemichannels (Cx HCs) and P2X7 receptors (P2X7Rs) in the skeletal myofibers. These findings were associated with an increased sarcolemma permeability, an elevated intracellular free Ca<sup>2&#x2b;</sup> concentration, and the activation of protein degradation via the ubiquitin&#x2013;proteasome pathway (<xref ref-type="bibr" rid="B1">Balboa et al., 2018</xref>). In addition, we described a moderate reduction in the mitochondrial oxygen consumption, a reduced mitochondrial membrane potential, and increased mitochondrial superoxide production (<xref ref-type="bibr" rid="B1">Balboa et al., 2018</xref>). Studies on the skeletal muscles of animals undergoing endotoxemia have also unveiled atrophy associated with the <italic>de novo</italic> expression of poorly selective membrane channels, including Cx HCs and P2X7Rs (<xref ref-type="bibr" rid="B8">Cea et al., 2019</xref>). Moreover, we found that the myofibers of mice deficient in Cx43 and Cx45 expression showed drastic resistance to a lipopolysaccharide- or denervation-induced reduction in the resting membrane potential, sarcolemma permeabilization, and increases in the sarcoplasmic Ca<sup>2&#x2b;</sup> concentrations in muscle fibers (<xref ref-type="bibr" rid="B8">Cea et al., 2019</xref>). Similar muscle protection was found in denervation or glucocorticoid-induced muscle atrophy (<xref ref-type="bibr" rid="B9">Cea et al., 2013</xref>; <xref ref-type="bibr" rid="B7">Cea et al., 2016</xref>), suggesting that the expression of non-selective channels is common in muscle atrophy of different etiologies.</p>
<p>Given that Cx HC expression worsens the pathological conditions of various skeletal muscles and occurs within the first hours after the onset of these pathologies (<xref ref-type="bibr" rid="B8">Cea et al., 2019</xref>; <xref ref-type="bibr" rid="B7">Cea et al., 2016</xref>), we decided to test how early Cx HC expression occurs following sepsis and whether it happens before the muscle atrophy associated with muscle protein degradation. We hypothesized that Cx43/Cx45 skeletal-myofiber-deficient animals may be protected from developing muscle depolarization and from the activation of protein degradation pathways induced by sepsis. Using a well-characterized model of sepsis (<xref ref-type="bibr" rid="B1">Balboa et al., 2018</xref>), we found that skeletal muscles express <italic>de novo</italic> Cx39, 43, and 45 as well as P2X7Rs as early as 6&#xa0;h after the beginning of sepsis, and that these are related to a reduction in the resting membrane potential and the activation of protein degradation. These findings could be relevant for future interventions and for developing novel therapeutic strategies for preventing sepsis-induced skeletal muscle atrophy.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec id="s2-1">
<title>Reagents</title>
<p>HEPES, leupeptin, pepstatin, phenylmethylsulphonyl fluoride (PMSF), N-benzyl-ptoluene (BTS), sulfonamide, collagenase type I, suramin, and ethidium (Etd<sup>&#x2b;</sup>) bromide were obtained from Sigma-Aldrich (St. Louis,MO, United States). The DMEM/F12 culture medium and fetal bovine serum albumin were from Gibco (Mary-land, United States). Tramadol was obtained from Genfar (Gentilly, Francia). Previously characterized anti-Cx39 and anti-Panx1 antibodies were used (<xref ref-type="bibr" rid="B30">Riquelme et al., 2013</xref>). Anti-atrogin1, anti-Murf, anti-Cx45, anti-Cx43, and P2X7R antibodies were obtained from Abcam (Cambridge, UK). Cy2-and Cy3-conjugated goat anti-rabbit IgG antibodies were purchased from Jackson Immuno Research (Indianapolis, IN, United States).</p>
</sec>
<sec id="s2-2">
<title>Animals</title>
<p>The present study was performed with approval from the bioethics committee of Pontificia Universidad Cat&#xf3;lica de Chile (No. 150323001). We used C57BL6 skeletal-muscle-deficient mice for Cx43 and Cx45 generated from breeding Cx43<sup>fl/fl</sup> mice and Cx45<sup>fl/fl</sup> mice with Myo-Cre mice, which express Cre recombinase under the control of a myogenin promoter and the MEF2C enhancer (<xref ref-type="bibr" rid="B9">Cea et al., 2013</xref>; <xref ref-type="bibr" rid="B12">Cisterna et al., 2016</xref>). The Cx43<sup>fl/fl</sup>Cx45<sup>fl/fl</sup> mice (hereafter referred to as Cre-) normally express Cx43 and Cx45, and the Cx43<sup>fl/fl</sup>Cx45<sup>fl/fl</sup>:Myo-Cre mice are double-inducible deficient in Cx43 and Cx45 (hereafter referred to as Cx3/45 deficient mice). The mice were kept in standard housing conditions with a 12-h/12-h dark/light cycle and food and water <italic>ad libitum</italic>. To minimize variability, only male mice were used in this study, focusing on sex-based differences in skeletal muscle physiology (<xref ref-type="bibr" rid="B19">Haizlip et al., 2015</xref>).</p>
<p>The tibialis anterior (TA) muscle and diaphragm were used for hematoxylin-eosin staining and immunofluorescence. For isolated fiber measurements, the flexor digitorum brevis (FDB) muscle was chosen due to the ease of isolating intact fibers without damage. Using different mouse muscles for distinct methodologies helps minimize the number of animals required. Importantly, both the FDB and TA muscles are composed predominantly of fast-twitch fibers, sharing similar metabolic and contractile properties, which supports the comparability of findings across these muscles.</p>
</sec>
<sec id="s2-3">
<title>Sepsis induction by cecal ligation and puncture</title>
<p>The mice were placed under CLP for six or 12&#xa0;h. For this, the mice were anesthetized using isoflurane (Baxter Healthcare, Guayama, Puerto Rico). The abdomen was shaved, and a midline incision (0.5&#xa0;cm) was made in the intraperitoneal area. The cecum was isolated, tied, and punctured once with a 21-gauge needle (0.8 &#xd7; 38&#xa0;mm), and a small amount of cecal material was extruded. The cecum was returned to the abdomen, and 200&#xa0;&#x3bc;L of PBS 1X was added to ensure sepsis. The incision was closed with a 20&#xa0;mm nylon surgical suture (Tagumedica S.A., Santiago, Chile). Sham controls were subjected to the same surgical protocol and cecal isolation, but the cecum was neither tied nor punctured. The control mice consisted of the sham group. A sham procedure was performed for each time point (0, 6, and 12&#xa0;h). However, no significant differences were observed between the sham groups at different time points for the parameters analyzed. Therefore, to minimize the number of mice used and to increase the sample size of the control group, all the sham groups were combined to form a single control group.</p>
</sec>
<sec id="s2-4">
<title>Mouse IL-6 immunoassay</title>
<p>The mouse IL-6 content was measured in 35&#xa0;&#x3bc;L of plasma using the Mouse IL-6 Quantikine ELISA Kit (R&#x26;D Systems, Inc; Minneapolis, MN, United States), according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2-5">
<title>Histological analysis</title>
<p>Freshly dissected TA muscles were embedded in a tissue-mounting OCT solution (Andes import, Chile) and fast frozen in liquid-nitrogen-cooled isopentane (Merck, Germany). Serial cryostat sections with a 16&#xa0;&#x3bc;m thickness were obtained, placed on glass slides (75 &#xd7; 25 mm, B&#x26;C, Germany), and fixed for 10&#xa0;min with 4% (wt/vol) paraformaldehyde (Electron Microscopy Sciences, United States) for immunofluorescence or cross-sectional area (CSA) analyses.</p>
</sec>
<sec id="s2-6">
<title>Cross-sectional area</title>
<p>The muscle fiber size was quantified by evaluating the cross-sectional area (CSA) of the fibers, measured as described previously (<xref ref-type="bibr" rid="B9">Cea et al., 2013</xref>). Briefly, cross-sections were stained with hematoxylin and eosin (H&#x26;E). The CSA was evaluated in multiple fibers from three images per mouse (4 mice per group) by using offline analyses with the ImageJ software (National Institutes of Health).</p>
</sec>
<sec id="s2-7">
<title>Immunofluorescence</title>
<p>To detect different proteins in cross-sections (16&#xa0;&#x3bc;m), the TA muscles sections were blocked for 1&#xa0;h in a blocking solution (1% BSA, 50&#xa0;mM NH4Cl, 0.01% Triton x-100, 1X PBS, and a pH of 7.4) and then incubated at 4&#xb0;C overnight with diluted primary anti-atrogin1 (1:300), anti-Murf 1 (1:300), anti-Cx39 (1:300), anti-Cx43 (1:300), anti-Cx45 (1:300), anti-Panx1 (1:300), or anti-P2X7 (1:200) antibodies (<xref ref-type="bibr" rid="B1">Balboa et al., 2018</xref>). The samples were washed 4 times with PBS 1X and then incubated with an appropriate dilution of Cy2-or Cy3-conjugated goat anti-rabbit IgG antibodies (1:300) for 1&#xa0;h in a dark room. The samples were washed 4 times with PBS 1X and one time with distilled water, and then mounted using Fluoromount-G&#x2122; with DAPI (Electron Microscopy Science, Hatfield, PA, United States) on glass slides. The images were generated using a Nikon Eclipse Ti micro-scope, and the fluorescence intensity was quantified with ImageJ. For each condition, histological sections from at least four mice were analyzed, with a minimum of three histological sections per mouse. For each section, three photographs were taken, and the fluorescence intensity of each photograph was quantified. The average fluorescence intensity for each image was plotted using a violin plot.</p>
</sec>
<sec id="s2-8">
<title>Isolation of skeletal myofibers</title>
<p>The myofibers of the mouse FDB muscles were isolated from anesthetized and sacrificed mice, as described previously (<xref ref-type="bibr" rid="B30">Riquelme et al., 2013</xref>). The muscles were immersed in a cultured medium (DMEM/F12 supplemented with 10% fetal bovine se-rum) containing 0.2% collagenase type I, and incubated for 2.5&#xa0;h at 37&#xb0;C. Then, they were transferred to a 15&#xa0;mL tube containing 3&#xa0;mL of Krebs buffer (in mM: 145 NaCl, 5 KCl, 3 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 5.6 glucose, 10 HEPES-Na, and a pH of 7,4) plus 10&#xa0;&#x3bc;M BTS (contraction inhibitor, to reduce muscle damage). The muscle tissue was incubated for 2&#xa0;min with 200&#xa0;&#x3bc;M suramin, a P2 receptor inhibitor, to prevent the effects of ATP release during the procedure. Then, the tissue was gently triturated by passing it 7 times through a wide-tip Pasteur pipette. The myofibers were left to decant for 7 min, and the sediment was washed with HEPES-buffered Krebs saline solution containing 10&#xa0;&#x3bc;M BTS. The myofibers were gently triturated again by passing them 15 times through a narrow tip to dissociate single myofibers. The dissociated myofibers were left to decant again for 7 min, after which the sediment was washed, resuspended in HEPES-buffered Krebs saline solution containing 10&#xa0;&#x3bc;M BTS, and placed in 1.5&#xa0;mL Eppendorf tubes until use for further analyses.</p>
</sec>
<sec id="s2-9">
<title>Dye uptake assay</title>
<p>The myofiber permeability was evaluated by assessing the ethidium (Etd<sup>&#x2b;</sup>) uptake using time-lapse measurements, as described previously (<xref ref-type="bibr" rid="B30">Riquelme et al., 2013</xref>). In brief, freshly FDB myofibers plated onto plastic culture dishes were washed twice with Krebs buffered solution. For the time-lapse measurements, the myofibers were incubated in a recording Krebs solution containing 5&#xa0;&#x3bc;M Etd<sup>&#x2b;</sup> and recorded for 5&#xa0;min in a control solution. They were subsequently recorded for 5&#xa0;min after an HC blocker (lanthanum ion (La<sup>3&#x2b;</sup>), 200&#xa0;&#xb5;M) was added to the Krebs solution (22). The Etd<sup>&#x2b;</sup> fluorescence was recorded in regions of interest (ROI) corresponding to the nuclei of the myofibers, using a Nikon Eclipse Ti inverted microscope and the NIS-Element software (Nikon, Tokio, Japan).</p>
</sec>
<sec id="s2-10">
<title>Oxygen consumption</title>
<p>The oxygen consumption of muscle fibers was measured as described previously (<xref ref-type="bibr" rid="B23">Kuznetsov et al., 2008</xref>). Fiber bundles from the soleus muscle (0.2&#x2013;0.8&#xa0;mg dry/wet) were separated along their longitudinal axis with a pair of needle-tipped forceps under magnification with an Olympus SZ61 microscope. The bundles were then treated with 50&#xa0;&#x3bc;g/mL of saponin for 30&#xa0;min in ice and subsequently washed in an MIR05 medium. High-resolution O<sup>2</sup> consumption measurements were conducted at 30&#xb0;C with the OROBOROS Oxygraph-2K (OROBOROS Instruments, Innsbruck, Austria).</p>
</sec>
<sec id="s2-11">
<title>Resting membrane potential (RMP)</title>
<p>The mice were anesthetized with 70&#xa0;&#xb5;L of a mixture consisting of xylazine and ketamine (1:3 proportion), and a conventional <italic>in vivo</italic> microelectrode recording technique was used (<xref ref-type="bibr" rid="B11">Cisterna et al., 2020</xref>). The flexor digirotium brevis (FDB) muscle was completely exposed and submerged in Krebs solution (pH of 7.4), and the RMP measurement was set to &#x201c;current clamp&#x201d; at 37&#xb0;C. The Ag-Cl reference electrode was inserted in a 3&#xa0;M KCl agarose bridge and submerged in Krebs solution to record superficial fibers from the FDB muscle. Each electrode was fabricated from a borosilicate capillary (A-M System, Inc., Cat &#x23; 596800) with the horizontal stretcher P97 (Sutter instruments, CA, EUA), and filled with a 3&#xa0;M KCl solution with electrode resistances within the range of 40&#x2013;50&#xa0;M&#x3a9;. The recorded RMP corresponded to the potential value measured when the microelectrode accessed the sarcoplasm, crossed the sarcolemma, and remained stable for 5&#xa0;s after impelling. All the experiments used an Olympus IX 51 inverted microscope with an Axopatch1-D amplifier (Molecular Devices, CA, EUA), a Digidata 1,322 digitalizer, and the Clampex 9.1 acquisition software.</p>
</sec>
<sec id="s2-12">
<title>Statistics</title>
<p>Based on the literature and our previous studies, we calculated the required sample size to detect significant differences in various parameters with a significance level of 0.05 and a power of 0.8, ensuring the minimum number of animals needed to observe significant effects, which was determined to be five in most cases.</p>
<p>The data for each condition are summarized in different type graphs as means &#xb1; standard error (SEM), where the number of mice per treatment group is indicated in the legend of each figure. The data were evaluated using non-parametric tests, specifically the Kruskal&#x2013;Wallis test followed by Dunn&#x2019;s multiple comparison test. Analyses were carried out using the GraphPad software. Significant differences between groups were considered when P &#x3c; 0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Characterization of the CLP-Induced sepsis model in early stages</title>
<p>Abundant evidence indicates that sepsis induces a myopathy characterized by reductions in muscle mass (<xref ref-type="bibr" rid="B31">Rocheteau et al., 2015</xref>). However, the mechanisms of this are not well understood. Previously, we observed that WT mice showed an almost 17% reduction in body weight 2 days after CLP, and this percentage remained until day 5, finally recovering at day 7 (<xref ref-type="bibr" rid="B1">Balboa et al., 2018</xref>). This weight reduction was attributed to the loss of muscular mass due to the documented muscular atrophy. However, at early time points, a decrease in mouse weight could have been due to a postoperative effect stemming from reduced water or food intake as a result of postoperative discomfort. The observed weight changes were similar between the control (sham) animals and those subjected to CLP in Cre- (Cx43<sup>fl/fl</sup>Cx45<sup>fl/fl</sup>) and Cx43/45-deficient (Cx43<sup>fl/fl</sup>Cx45<sup>fl/fl</sup>: Myo-Cre) mice at 6 and 12&#xa0;h (<xref ref-type="fig" rid="F1">Figure 1A</xref>). At 48&#xa0;h, the mice begin to experience significant weight loss, which is attenuated in Cx43/45-deficient mice (<xref ref-type="sec" rid="s12">Supplementary Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>
<bold>(A)</bold> Animal Weight Changes after CLP-Induced Sepsis. Body weight over time in control and at 6 and 12&#xa0;h after CLP, a sepsis model. Body weight loss in Cx43fl/flCx45fl/fl and Cx43fl/flCx45fl/fl:M-C (Cx43/45 deficient) mice. <bold>(B)</bold> Quantification of plasma IL-6 concentration in control and CLP mice at 6 and 12&#xa0;h after CLP. The cytokine was quantified using the Mouse IL-6 Quantikine ELISA Kit (R&#x26;D Systems, Inc; Minneapolis, United States). Statistical comparisons were made with the GraphPad Prism software using non-parametric tests, specifically the Kruskal&#x2013;Wallis test followed by Dunn&#x2019;s multiple comparison test. The error bars represent the standard error of the mean (SEM). &#x2a;p &#x3c; 0.05, &#x2a;&#x2a;p &#x3c; 0.01, ns: not significant. n &#x3d; at least four for each condition.</p>
</caption>
<graphic xlink:href="fphys-16-1514769-g001.tif"/>
</fig>
<p>As previously demonstrated, skeletal muscle IL-6 production contributes to the overall circulating IL-6 levels during exposure to a septic peritoneal infection (<xref ref-type="bibr" rid="B24">Laitano et al., 2021</xref>). We aimed to evaluate whether differences in the IL-6 levels existed in our model. As shown in <xref ref-type="fig" rid="F1">Figure 1B</xref>, a tenfold increase in the IL-6 levels was observed in Cre-mice at 6&#xa0;h post-CLP compared to the controls, and this increased approximately tenfold at 12&#xa0;h. Conversely, in Cx43/45-deficient mice, only a fivefold increase in the IL-6 levels was observed at 6 and 12&#xa0;h post-CLP, suggesting that there could be less muscle inflammation in Cx43/45-deficient mice. Hematoxylin and eosin staining revealed immune cell infiltration in muscles of Cre-mice at 12&#xa0;h post-CLP, with multiple infiltration foci observed. In contrast, muscles of Cre &#x2b; mice exhibited very few foci of immune cell infiltration, further supporting the observation of reduced muscle inflammation in these mice (<xref ref-type="sec" rid="s12">Supplementary Figure 2C</xref>).</p>
</sec>
<sec id="s3-2">
<title>Upregulation of ubiquitin&#x2013;proteasome degradation proteins in peripheral and diaphragm muscles during CLP-induced sepsis at 6&#x2013;12 h</title>
<p>As we have previously shown that sepsis induces a decrease in CSA at 7 days (<xref ref-type="bibr" rid="B1">Balboa et al., 2018</xref>), we wanted to evaluate the CSA at early times. At 6 and 12&#xa0;h post-sepsis induction, we observed no significant changes CSA (<xref ref-type="sec" rid="s12">Supplementary Figure 2</xref>); however, levels of atrogins and MuRF, proteins associated with muscle atrophy (<xref ref-type="bibr" rid="B35">Tiao et al., 1994</xref>), were increased in Cre-mice. Notably, this increase was not observed in deficient CXs43/45 mice (<xref ref-type="fig" rid="F2">Figure 2A</xref>). On the other hand, the diaphragm muscles showed an increase in the Murf immunoreactivity at 6 and 12&#xa0;h after CLP in Cre-mice and at 12&#xa0;h in Cx43/45 deficient mice (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>CLP-induced sepsis increases the immunoreactivity of atrogin-1 and Murf. Immunofluorescence over time was evaluated in control mice and at 6 and 12&#xa0;h after CLP. <bold>(A)</bold> Representative images and quantification of immunofluorescence for atrogin-1 and Murf in tibialis anterior muscle sections from control and CLP mice at different time points post-CLP. <bold>(B)</bold> Representative images and quantification of immunofluorescence for atrogin-1 and Murf in diaphragm muscle sections from control and CLP mice at different time points post-CLP. For each condition, histological sections from at least four mice were analyzed, with a minimum of three histological sections per mouse. Fluorescence intensity was quantified from each section, and the average fluorescence intensity for each image was plotted using a violin plot. Statistical comparisons were performed using GraphPad Prism software, with non-parametric tests (Kruskal&#x2013;Wallis test followed by Dunn&#x2019;s multiple comparison test). Error bars represent the standard error of the mean (SEM) (&#x2a;p &#x3c; 0.05, &#x2a;&#x2a;p &#x3c; 0.01, &#x2a;&#x2a;&#x2a;p &#x3c; 0.001).</p>
</caption>
<graphic xlink:href="fphys-16-1514769-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Early increase in Cx39, Cx43, and Cx45 hemichannel expression and decrease in resting membrane potential in peripheral and diaphragm muscles following CLP-induced sepsis</title>
<p>Previous studies have described that denervated skeletal muscles show the <italic>de novo</italic> expression of Cx39, 43, and 45&#xa0;HCs, in addition to P2X7Rs, and the upregulation of pannexin1 (Panx1), which play a relevant role in muscle atrophy (<xref ref-type="bibr" rid="B9">Cea et al., 2013</xref>; <xref ref-type="bibr" rid="B12">Cisterna et al., 2016</xref>). Nevertheless, there is currently no evidence regarding the early expression of membrane channel-forming proteins in the skeletal muscles of mice subjected to CLP. To study this possibility, we evaluated the reactivity of Cx39, 43, and 45, Panx1, and P2X7Rs in slices of the TA and diaphragm muscles from Cre- and Cx43/45-deficient mice subjected or not to CLP.</p>
<p>In the TA muscles of Cre-mice Cx45 increased at 6&#xa0;h, and Cx43 increased at 12&#xa0;h. Meanwhile, Panx1 showed no significant changes, and P2X7Rs decreased at 12&#xa0;h. In contrast, no changes were observed in Cx43/45-deficient mice in the expression of Cx39, Cx43, and Cx45&#xa0;at both 6 and 12&#xa0;h post-CLP. However, Panx1 and P2X7Rs increased at 6&#xa0;h post-CLP (<xref ref-type="fig" rid="F3">Figures 3A&#x2013;E</xref>). We found similar changes in the diaphragm muscles to those observed in the TA muscles (<xref ref-type="sec" rid="s12">Supplementary Figure 3</xref>). All the proteins analyzed were mainly detected in the contours of the myofibers, and were likely associated with the sarcolemma.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Cx43/45-deficient mice are protected against the sepsis-induced <italic>de novo</italic> expression of connexin hemichannels in the sarcolemma of skeletal muscle. Representative images and quantification of immunofluorescence for <bold>(A)</bold> Cx39, <bold>(B)</bold> Cx43, <bold>(C)</bold> Cx45, <bold>(D)</bold> Panx1, and <bold>(E)</bold> P2X7Rs in tibialis anterior muscle sections from control and CLP mice at different time points post-CLP, for Cre- (Cx43<sup>fl/fl</sup>Cx45<sup>fl/fl</sup>) and Cx43/Cx45-expression-deficient (Cx43<sup>fl/fl</sup> Cx45<sup>fl/fl</sup>) mice. Fluorescence intensity was quantified in at least three histological sections analyzed from a minimum of four mice per treatment group. The data is presented using box and violin plots. Statistical comparisons were performed using GraphPad Prism software with non-parametric tests (Kruskal&#x2013;Wallis test followed by Dunn&#x2019;s multiple comparison test). Error bars represent the standard error of the mean (SEM) (&#x2a;p &#x3c; 0.05, &#x2a;&#x2a;p &#x3c; 0.01, &#x2a;&#x2a;&#x2a;p &#x3c; 0.001).</p>
</caption>
<graphic xlink:href="fphys-16-1514769-g003.tif"/>
</fig>
<p>Given that the <italic>de novo</italic> expression of connexins after CLP was observed in the myofibers of Cre-animals, we aimed to assess whether the expression of these connexins on the sarcolemma had an impact on the resting membrane potential (RMP) of myofibers due to an increase in the ion flux through the HCs, as described before (<xref ref-type="bibr" rid="B11">Cisterna et al., 2020</xref>). Furthermore, the sarcolemma of the skeletal myofibers in mice exposed to sepsis becomes electrically unexcitable (<xref ref-type="bibr" rid="B36">Trojaborg et al., 2001</xref>). Accordingly, we evaluated whether or not the RMP is altered during early sepsis in Cre- and Cx43/45-deficient mice subjected to CLP. We observed that the RMP in Cre-animals decreased significantly at 6&#xa0;h and 12&#xa0;h after CLP. In contrast, Cx43/45 animals were protected, and their RMP was kept stable over time (<xref ref-type="fig" rid="F4">Figure 4A</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Sepsis Augments Connexin Hemichannel Aperture Probability, which is Prevented in Cx43/45 deficient mice. <bold>(A)</bold> Resting membrane potential (RMP) was evaluated at 0, 6 and 12&#xa0;h of CLP in control and Cx43/45 deficient mice. <bold>(B)</bold> The permeability of the sarcolemma was measured in time-lapse experiments of ethidium (Etd<sup>&#x2b;</sup>) uptake in isolated skeletal myofibers from the FDB muscle of control and CLP mice after 6 and 12&#xa0;h. Ethidium uptake was assessed in at least five isolated fibers from a minimum of four mice for each treatment group. Statistical comparisons were conducted by utilizing GraphPad Prism software and non-parametric tests, specifically the Kruskal&#x2013;Wallis test followed by Dunn&#x2019;s multiple comparison test. The error bars represent the standard error of the mean (SEM) (&#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001).</p>
</caption>
<graphic xlink:href="fphys-16-1514769-g004.tif"/>
</fig>
<p>Cx HCs allow for the flow of ions such as Na<sup>&#x2b;</sup> and Ca<sup>2&#x2b;</sup> [24], and given our previous results indicating that Cx HCs were expressed in the muscles and the RMP was altered in CLP Cre-mice, we decided to evaluate the Cx HC activity in freshly isolated FDB myofibers using the ethidium (Etd&#x2b;) uptake technique. We found that the Etd<sup>&#x2b;</sup> uptake increased in septic Cre-animals as early as 6&#xa0;h compared with control animals, but it did not increase in septic Cx43/45-deficient animals. In addition, the Etd<sup>&#x2b;</sup> uptake was reverted by adding La<sup>3&#x2b;</sup>, a non-selective Cx HC blocker (<xref ref-type="bibr" rid="B33">Shoji et al., 2014</xref>). These results suggest that sepsis increases the sarcolemma permeability through Cx HCs (<xref ref-type="fig" rid="F4">Figure 4B</xref>).</p>
</sec>
<sec id="s3-4">
<title>CLP induces similar changes in the mitochondrial oxygen consumption rate and the ex-pression of mitochondrial respiratory chain components in both Cre- and Cx43/45-deficient mice</title>
<p>Changes induced by acute inflammatory conditions, such as sepsis, are linked to the dysfunction of mitochondrial components in muscle [30]. Moreover, alterations in the sarcolemma permeability and RMP secondary to ion influx, such as Ca<sup>2&#x2b;</sup>, are important for the correct functioning of mitochondria (<xref ref-type="bibr" rid="B32">Ruiz-Meana et al., 2009</xref>; <xref ref-type="bibr" rid="B13">Contreras et al., 2010</xref>). To determine the mitochondrial function in CLP mice, we measured the mitochondrial oxygen consumption rate (OCR) using permeabilized fibers from the soleus muscles. The mitochondrial oxygen consumption rate was similar between Cre- and Cx43/45-deficient mice across all the evaluated parameters (<xref ref-type="sec" rid="s12">Supplementary Figure 4</xref>). CLP at 6 and 12&#xa0;h did not affect the mitochondrial function in our model. This suggests that mitochondria can withstand the changes observed in the other results.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In the present study, which was carried out on an early model of sepsis, connexin expression was observed to occur early during sepsis and was functionally active as HCs and associated with sarcolemma depolarization, as well as the activation of muscle protein degradation pathways. We did not observe mitochondrial dysfunction (MD), suggesting that MD can occur later or is a downstream phenomenon of sarcolemma Cx HC expression.</p>
<p>IL-6 increased with CLP, being more pronounced in Cre-mice than in Cx43/45-deficient mice. Although this inflammation was lower in myofiber Cx43/45-deficient mice, it was not absent. It should be noted that this measurement was performed in plasma, thus representing systemic inflammation induced by sepsis. Activated macrophages, as well as other cell types, can generate IL-6 and contribute a significant amount of pro-inflammatory cytokines, including IL-6. However, given that Cx43/45-deficient mice were muscle-specific, the decrease in inflammation suggests that there is less inflammation at the muscular level. It should be highlighted that the non-expression of connexins at the muscular level impacted systemic inflammation. This suggests that skeletal myofibers participate by orchestrating a relevant phenomenon in systemic inflammation induced by CLP or that the muscle itself becomes inflamed, and the non-expression of connexin protects the muscle from this inflammation. The expression of connexins by myofibers could have resulted from the effect of pro-inflammatory mediators, as previously shown in freshly isolated myofibers treated with TNF-&#x3b1; plus IL-1&#x3b2; (<xref ref-type="bibr" rid="B8">Cea et al., 2019</xref>).</p>
<p>Changes in the total body weight (BW) can influence the gain and loss of muscle mass (<xref ref-type="bibr" rid="B27">McNair et al., 2020</xref>). We observed that, in CLP mice, weight loss began at 48&#xa0;h (<xref ref-type="sec" rid="s12">Supplementary Figure 1</xref>), which could not be explained by a decreased food intake. Again, considering the myofiber specificity of Cx43/45 muscle-deficient mice, the non-expression of connexins could protect them against weight loss, given their effect on the muscle. However, we hypothesize that decreases in muscle mass begin later than 24&#xa0;h, as this involves processes that require more time to occur.</p>
<p>Since 6 and 12&#xa0;h is a very early time point to observe a decrease in CSA, we did not expect to see differences between Cre- and Cx43/45-deficient mice. However, we analyzed the activation of the protein degradation cascade induced by the Atrogin and Murf proteins and found that they were elevated at 6&#xa0;h post-CLP in Cre-mice. Notably, these proteins were not elevated in the TA muscle from Cx43/45-deficient mice, suggesting that the expression of connexins in the sarcolemma induced the activation of this pathway. This may be explained by reductions in the myofiber RMP observed in these mice, which are associated with ion influx and could contribute to the activation of the ubiquitin&#x2013;proteasome pathway. In addition, the influx of Ca<sup>2&#x2b;</sup> could be responsible for the induction of Murf and Atrogin expression and activation (<xref ref-type="bibr" rid="B20">Ham et al., 2014</xref>).</p>
<p>On the other hand, what we did not expect was the elevated Murf1 levels observed in the diaphragm. At 12&#xa0;h, Murf1 expression was significantly increased in the diaphragm of Cx43/45-deficient mice, which we consider an unexpected result. This finding could potentially be related to the increased expression of Panx1, the different fiber composition in the diaphragm compared to the TA, or other unidentified factors. Further studies are required to determine the underlying mechanisms responsible for this differential response between the diaphragm and the TA muscle in Cx43/45-deficient mice.</p>
<p>Considering that all the connexin proteins observed using immunofluorescence were in the periphery of the cells, their presence on the sarcolemma can be suggested. Furthermore, given that cells from septic Cx43/45-deficient mice did not show permeability to Etd<sup>&#x2b;</sup> and cells from Cre-mice were permeable to Etd<sup>&#x2b;</sup>, which was completely blocked by La<sup>3&#x2b;</sup>, the increase in the sarcolemma permeability was likely primarily mediated by Cx HCs. Neither Panx1 nor P2X7Rs were blocked by La<sup>3&#x2b;</sup> (<xref ref-type="bibr" rid="B33">Shoji et al., 2014</xref>), suggesting that only Cx HCs, which are absent in normal muscles as reported previously (<xref ref-type="bibr" rid="B9">Cea et al., 2013</xref>; <xref ref-type="bibr" rid="B30">Riquelme et al., 2013</xref>; <xref ref-type="bibr" rid="B12">Cisterna et al., 2016</xref>), are the main contributors to the increase in the sarcolemma permeability. This increase in the sarcolemma permeability could also largely explain the RMP reduction and reduced excitability of myofibers. The observed upregulation of P2X7R and persistent expression of Panx1 in the muscle tissues of Cx43/45-deficient mice observed at 6&#xa0;h CLP likely reflects a multifaceted response. Given the absence of Cx43-and Cx45-based hemichannels, the increase in P2X7R and Panx1 expression may represent a systemic response to sepsis, as both proteins are known to be upregulated during inflammatory conditions (<xref ref-type="bibr" rid="B8">Cea et al., 2019</xref>) and contribute to immune cell recruitment and inflammasome activation (<xref ref-type="bibr" rid="B26">Loureiro et al., 2022</xref>; <xref ref-type="bibr" rid="B10">Chen et al., 2023</xref>). Further studies are required to understand this response better.</p>
<p>The peripheral muscles of septic patients have been described as showing signs of bioenergetic failure, comprising oxidative stress, MD, and ATP depletion (<xref ref-type="bibr" rid="B2">Baracos et al., 1986</xref>). In our model, we did not observe MD in the early stages of sepsis (6 and 12&#xa0;h post-CLP), strongly suggesting that sarcolemma channelopathy occurs before MD. It is possible that the loss of the electrochemical gradient across the sarcolemma, caused by the expression of functional, poorly selective sarcolemma channels, could reduce the mitochondrial membrane potentials (MMPs). The latter is greatly affected by increases in the intracellular Na<sup>&#x2b;</sup> or Ca<sup>2&#x2b;</sup> signals, but MD manifests later, based on our observations, only becoming apparent at 48&#xa0;h (<xref ref-type="sec" rid="s12">Supplementary Figure 2</xref>). Our findings highlight the potential role of sarcolemma channelopathy in the early pathogenesis of sepsis-induced muscle dysfunction. Furthermore, the protective effect observed in Cx43/45-deficient mice, both in terms of inflammation and muscle preservation, suggests that targeting sarcolemma Cx HCs could be a potential therapeutic strategy for mitigating sepsis-induced muscle pathology. The sued of selective inhibitors of Cx HCs such as D4 molecule (<xref ref-type="bibr" rid="B11">Cisterna et al., 2020</xref>), Gap-19 or Gap-26 could be considered for therapeutical use.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. It can be accessed on Figshare repository, <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://figshare.com/s/7fc1c880ef780798bb23">https://figshare.com/s/7fc1c880ef780798bb23</ext-link>.</p>
</sec>
<sec sec-type="ethics-statement" id="s6">
<title>Ethics statement</title>
<p>The animal study was approved by the Bioethics committee of Pontificia Universidad Cat&#xf3;lica de Chile (Proyect No. 150323001). The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>EB: Data curation, Formal Analysis, Funding acquisition, Investigation, Supervision, Writing&#x2013;original draft, Writing&#x2013;review and editing. FS: Data curation, Formal Analysis, Writing&#x2013;original draft. LC: Data curation, Writing&#x2013;review and editing. AV: Data curation, Writing&#x2013;review and editing. TR: Funding acquisition, Supervision, Writing&#x2013;review and editing. JS: Conceptualization, Funding acquisition, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s8">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was partially funded by Fondo Nacional de Ciencia y Tecnolog&#xed;a (FOND-ECYT), grants 1141092 (to TR and JS) and 1231523 (to JS); FONDECYT, grant 3160594 and 11230689 (to EB); DIUA 265-2023 de la Vicerrector&#xed;a de Investigaci&#xf3;n y Doctorados (to LC); and ICM-Econom&#xed;a P09-022-F Centro Interdisciplinario de Neurociencias de Valpara&#xed;so (to JS).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s10">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphys.2025.1514769/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphys.2025.1514769/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image1.tif" id="SM1" mimetype="application/tif" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.pdf" id="SM2" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balboa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Saavedra-Leiva</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cea</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Escamilla</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Sepsis-induced channelopathy in skeletal muscles is associated with expression of non-selective channels</article-title>. <source>Shock</source> <volume>49</volume> (<issue>2</issue>), <fpage>221</fpage>&#x2013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0000000000000916</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baracos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>A. L.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>Influence of calcium and other divalent cations on protein turnover in rat skeletal muscle</article-title>. <source>Am. J. Physiol.</source> <volume>250</volume> (<issue>6 Pt 1</issue>), <fpage>E702</fpage>&#x2013;<lpage>E710</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.1986.250.6.E702</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vogelmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Preissing</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Stiefel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019&#x2014; results from a systematic review and meta-analysis</article-title>. <source>Crit. Care</source> <volume>24</volume> (<issue>1</issue>), <fpage>239</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-02950-2</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilevicius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dragosavac</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dragosavac</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ara&#xfa;jo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Falc&#xe3;o</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Terzi</surname>
<given-names>R. G.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Multiple organ failure in septic patients</article-title>. <source>Braz J. Infect. Dis.</source> <volume>5</volume> (<issue>3</issue>), <fpage>103</fpage>&#x2013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1590/s1413-86702001000300001</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brealey</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Karyampudi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jacques</surname>
<given-names>T. S.</given-names>
</name>
<name>
<surname>Novelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stidwill</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure</article-title>. <source>Am. J. Physiol. Regul. Integr. Comp. Physiol.</source> <volume>286</volume> (<issue>3</issue>), <fpage>R491</fpage>&#x2013;<lpage>R497</lpage>. <pub-id pub-id-type="doi">10.1152/ajpregu.00432.2003</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callahan</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Supinski</surname>
<given-names>G. S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Sepsis-induced myopathy</article-title>. <source>Crit. Care Med.</source> <volume>37</volume> (<issue>10 Suppl. l</issue>), <fpage>S354</fpage>&#x2013;<lpage>S367</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e3181b6e439</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cea</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Balboa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Puebla</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Cisterna</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Escamilla</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Dexamethasone-induced muscular atrophy is mediated by functional expression of connexin-based hemichannels</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1862</volume> (<issue>10</issue>), <fpage>1891</fpage>&#x2013;<lpage>1899</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.07.003</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cea</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Balboa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Puebla</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Branes</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Escamilla</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>
<italic>De novo</italic> expression of functional connexins 43 and 45 hemichannels increases sarcolemmal permeability of skeletal myofibers during endotoxemia</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source> <volume>1865</volume> (<issue>10</issue>), <fpage>2765</fpage>&#x2013;<lpage>2773</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2019.06.014</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cea</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Cisterna</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Puebla</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Figueroa</surname>
<given-names>X. F.</given-names>
</name>
<name>
<surname>Cardozo</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>
<italic>De novo</italic> expression of connexin hemichannels in denervated fast skeletal muscles leads to atrophy</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>110</volume> (<issue>40</issue>), <fpage>16229</fpage>&#x2013;<lpage>16234</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1312331110</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Pannexin1: insight into inflammatory conditions and its potential involvement in multiple organ dysfunction syndrome</article-title>. <source>Front. Immunol.</source> <volume>14</volume>, <fpage>1217366</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1217366</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cisterna</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Puebla</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Escamilla</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lagos</surname>
<given-names>C. F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Active acetylcholine receptors prevent the atrophy of skeletal muscles and favor reinnervation</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>1073</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-14063-8</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cisterna</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Puebla</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saez</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Connexin hemichannels explain the ionic imbalance and lead to atrophy in denervated skeletal muscles</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1862</volume> (<issue>11</issue>), <fpage>2168</fpage>&#x2013;<lpage>2176</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.08.020</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Contreras</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Drago</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zampese</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pozzan</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Mitochondria: the calcium connection</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1797</volume> (<issue>6-7</issue>), <fpage>607</fpage>&#x2013;<lpage>618</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2010.05.005</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Sharshar</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lefaucheur</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Authier</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Durand-Zaleski</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Boussarsar</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Paresis acquired in the intensive care unit: a prospective multicenter study</article-title>. <source>JAMA</source> <volume>288</volume> (<issue>22</issue>), <fpage>2859</fpage>&#x2013;<lpage>2867</lpage>. <pub-id pub-id-type="doi">10.1001/jama.288.22.2859</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dougnac</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Mercado</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Cornejo</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Cariaga</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Hern&#xe1;ndez</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Andresen</surname>
<given-names>H. M.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Prevalencia de sepsis grave en las Unidades de Cuidado Intensivo: Primer estudio nacional multic&#xe9;ntrico</article-title>. <source>Rev. m&#xe9;dica Chile</source> <volume>135</volume>, <fpage>620</fpage>&#x2013;<lpage>630</lpage>. <pub-id pub-id-type="doi">10.4067/s0034-98872007000500010</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eikermann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gerwig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ochterbeck</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Beiderlinden</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koeppen</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Muscle force and fatigue in patients with sepsis and multiorgan failure</article-title>. <source>Intensive Care Med.</source> <volume>32</volume> (<issue>2</issue>), <fpage>251</fpage>&#x2013;<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-005-0029-x</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fern&#xe1;ndez-Lorente</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Esteban</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salinero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Traba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Palencia</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Critical illness myopathy. Neurophysiological and muscular biopsy assessment in 33 patients</article-title>. <source>Rev. Neurol.</source> <volume>50</volume> (<issue>12</issue>), <fpage>718</fpage>&#x2013;<lpage>726</lpage>.</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleischmann-Struzek</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mellhammar</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cassini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Schlattmann</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis</article-title>. <source>Intensive Care Med.</source> <volume>46</volume> (<issue>8</issue>), <fpage>1552</fpage>&#x2013;<lpage>1562</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-06151-x</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haizlip</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Leinwand</surname>
<given-names>L. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Sex-based differences in skeletal muscle kinetics and fiber-type composition</article-title>. <source>Physiol. (Bethesda)</source> <volume>30</volume> (<issue>1</issue>), <fpage>30</fpage>&#x2013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1152/physiol.00024.2014</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ham</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>K. T.</given-names>
</name>
<name>
<surname>Chee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Koopman</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia</article-title>. <source>Clin. Nutr.</source> <volume>33</volume> (<issue>3</issue>), <fpage>448</fpage>&#x2013;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1016/j.clnu.2013.06.013</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hermans</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Van den Berghe</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Clinical review: intensive care unit acquired weakness</article-title>. <source>Crit. Care</source> <volume>19</volume> (<issue>1</issue>), <fpage>274</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-015-0993-7</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Rich</surname>
<given-names>M. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Mechanisms of neuromuscular dysfunction in critical illness</article-title>. <source>Crit. Care Clin.</source> <volume>24</volume> (<issue>1</issue>), <fpage>165</fpage>&#x2013;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccc.2007.10.004</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuznetsov</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Veksler</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gellerich</surname>
<given-names>F. N.</given-names>
</name>
<name>
<surname>Saks</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Margreiter</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>W. S.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Analysis of mitochondrial function <italic>in situ</italic> in permeabilized muscle fibers, tissues and cells</article-title>. <source>Nat. Protoc.</source> <volume>3</volume> (<issue>6</issue>), <fpage>965</fpage>&#x2013;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.61</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laitano</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>G. P.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Mattingly</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>K. O.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Skeletal muscle interleukin-6 contributes to the innate immune response in septic mice</article-title>. <source>Shock</source> <volume>55</volume> (<issue>5</issue>), <fpage>676</fpage>&#x2013;<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0000000000001641</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Vary</surname>
<given-names>T. C.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Regulation of muscle protein synthesis during sepsis and inflammation</article-title>. <source>Am. J. Physiol. Endocrinol. Metab.</source> <volume>293</volume> (<issue>2</issue>), <fpage>E453</fpage>&#x2013;<lpage>E459</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.00204.2007</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loureiro</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Moura-Neto</surname>
<given-names>L. I.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>P. I. M.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>M. B. S.</given-names>
</name>
<name>
<surname>Leit&#xe3;o</surname>
<given-names>R. F. C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Role of Pannexin-1-P2X7R signaling on cell death and pro-inflammatory mediator expression induced by Clostridioides difficile toxins in enteric glia</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>956340</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.956340</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNair</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Marcello</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Bruns</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Changes in muscle mass and composition by exercise and hypoxia as assessed by DEXA in mice</article-title>. <source>Med. Kaunas.</source> <volume>56</volume> (<issue>9</issue>), <fpage>446</fpage>. <pub-id pub-id-type="doi">10.3390/medicina56090446</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prauchner</surname>
<given-names>C. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Oxidative stress in sepsis: pathophysiological implications justifying antioxidant co-therapy</article-title>. <source>Burns</source> <volume>43</volume> (<issue>3</issue>), <fpage>471</fpage>&#x2013;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1016/j.burns.2016.09.023</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prest</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rajah</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Prest</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Sathananthan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jeganathan</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Sepsis-related mortality rates and trends based on site of infection</article-title>. <source>Crit. Care Explor</source> <volume>4</volume> (<issue>10</issue>), <fpage>e0775</fpage>. <pub-id pub-id-type="doi">10.1097/CCE.0000000000000775</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riquelme</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Cea</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Vega</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Boric</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Monyer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>M. V.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>The ATP required for potentiation of skeletal muscle contraction is released via pannexin hemichannels</article-title>. <source>Neuropharmacology</source> <volume>75</volume>, <fpage>594</fpage>&#x2013;<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.03.022</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocheteau</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chatre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Briand</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mebarki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jouvion</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bardon</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy</article-title>. <source>Nat. Commun.</source> <volume>6</volume>, <fpage>10145</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms10145</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz-Meana</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abell&#xe1;n</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mir&#xf3;-Casas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Agull&#xf3;</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Garcia-Dorado</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Role of sarcoplasmic reticulum in mitochondrial permeability transition and cardiomyocyte death during reperfusion</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source> <volume>297</volume> (<issue>4</issue>), <fpage>H1281</fpage>&#x2013;<lpage>H1289</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00435.2009</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoji</surname>
<given-names>K. F.</given-names>
</name>
<name>
<surname>Saez</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Harcha</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Aguila</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Saez</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Pannexin1 channels act downstream of P2X 7 receptors in ATP-induced murine T-cell death</article-title>. <source>Channels (Austin)</source> <volume>8</volume> (<issue>2</issue>), <fpage>142</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.4161/chan.28122</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Deutschman</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Seymour</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Shankar-Hari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Annane</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>. <source>JAMA</source> <volume>315</volume> (<issue>8</issue>), <fpage>801</fpage>&#x2013;<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Samuels</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>1994</year>). <article-title>Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle</article-title>. <source>J. Clin. Invest</source> <volume>94</volume> (<issue>6</issue>), <fpage>2255</fpage>&#x2013;<lpage>2264</lpage>. <pub-id pub-id-type="doi">10.1172/JCI117588</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trojaborg</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Weimer</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Hays</surname>
<given-names>A. P.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy--a reappraisal</article-title>. <source>Clin. Neurophysiol.</source> <volume>112</volume> (<issue>9</issue>), <fpage>1586</fpage>&#x2013;<lpage>1593</lpage>. <pub-id pub-id-type="doi">10.1016/s1388-2457(01)00572-7</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wasyluk</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zwolak</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Metabolic alterations in sepsis</article-title>. <source>J. Clin. Med.</source> <volume>10</volume> (<issue>11</issue>), <fpage>2412</fpage>. <pub-id pub-id-type="doi">10.3390/jcm10112412</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>